[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2619332T3 - Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma - Google Patents

Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma Download PDF

Info

Publication number
ES2619332T3
ES2619332T3 ES13002327T ES13002327T ES2619332T3 ES 2619332 T3 ES2619332 T3 ES 2619332T3 ES 13002327 T ES13002327 T ES 13002327T ES 13002327 T ES13002327 T ES 13002327T ES 2619332 T3 ES2619332 T3 ES 2619332T3
Authority
ES
Spain
Prior art keywords
kits
bone
methods
alkaline phosphatase
directed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13002327T
Other languages
English (en)
Inventor
Philippe Crine
Guy Boileau
Thomas P. Loisel
Isabelle Lemire
Pierre Leonard
Robert Heft
Hal Landy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2619332T3 publication Critical patent/ES2619332T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001—Alkaline phosphatase (3.1.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cereal-Derived Products (AREA)
  • Adornments (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Una composición farmacéutica que comprende un polipéptido que tiene la secuencia expuesta en SEC ID NO: 4 y un soporte farmacéuticamente aceptable que comprende cloruro de sodio y/o fosfato de sodio.
ES13002327T 2007-05-11 2008-05-12 Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma Active ES2619332T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91758907P 2007-05-11 2007-05-11

Publications (1)

Publication Number Publication Date
ES2619332T3 true ES2619332T3 (es) 2017-06-26

Family

ID=40001639

Family Applications (3)

Application Number Title Priority Date Filing Date
ES11004496.3T Active ES2471915T3 (es) 2007-05-11 2008-05-12 Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma
ES08757088T Active ES2380546T3 (es) 2007-05-11 2008-05-12 Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma
ES13002327T Active ES2619332T3 (es) 2007-05-11 2008-05-12 Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES11004496.3T Active ES2471915T3 (es) 2007-05-11 2008-05-12 Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma
ES08757088T Active ES2380546T3 (es) 2007-05-11 2008-05-12 Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma

Country Status (25)

Country Link
US (1) US20100297119A1 (es)
EP (3) EP2662448B1 (es)
JP (1) JP5732603B2 (es)
AT (1) ATE536413T1 (es)
AU (1) AU2008250945B2 (es)
BR (2) BR122019000505B1 (es)
CA (1) CA2687001C (es)
CY (1) CY2016005I1 (es)
DE (1) DE202008018131U1 (es)
DK (3) DK2158319T3 (es)
ES (3) ES2471915T3 (es)
HK (3) HK1141047A1 (es)
HR (1) HRP20140416T1 (es)
HU (2) HUE031655T2 (es)
IL (1) IL202057A0 (es)
LT (1) LTC2368999I2 (es)
LU (1) LU92976I2 (es)
ME (1) ME01828B (es)
NL (1) NL300798I1 (es)
NO (1) NO2016002I2 (es)
PL (3) PL2368999T3 (es)
PT (3) PT2368999E (es)
RS (1) RS53302B (es)
SI (2) SI2662448T1 (es)
WO (1) WO2008138131A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2348114B1 (en) * 2004-04-21 2018-07-25 Alexion Pharmaceuticals, Inc. Bone delivery conjugates and method of using same to target proteins to bone
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
US8784833B2 (en) * 2006-06-27 2014-07-22 Saint Louis University Prenatal enzyme replacement therapy for hypophosphatasia
HUE026953T2 (en) 2007-06-01 2016-08-29 Univ Maryland Immunoglobulin constant region FC receptor binding agents
WO2011113027A2 (en) 2010-03-12 2011-09-15 Synageva Biopharma Corp Npp1 fusion proteins
SG185079A1 (en) * 2010-04-30 2012-12-28 Alexion Pharma Internat Sarl Methods, compositions, and kits for the treatment of matrix mineralization disorders
PT2598533T (pt) 2010-07-28 2019-05-08 Gliknik Inc Proteínas de fusão de fragmentos de proteínas humanas naturais para criar composições fc de imunoglobulina multimerizada de forma ordenada
EP2658979B1 (en) 2010-12-27 2018-02-14 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
SG11201401605QA (en) * 2011-10-19 2014-09-26 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
CA2882296A1 (en) 2012-08-20 2014-02-27 Gliknik Inc. Molecules with antigen binding and polyvalent fc gamma receptor binding activity
MX369041B (es) 2014-01-24 2019-10-25 Am Pharma Bv Proteinas quimericas tipo fosfatasa alcalina.
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
MX2017007392A (es) * 2014-12-05 2019-01-24 Alexion Pharma Inc Tratamiento de convulsiones con fosfatasa alcalina recombinante.
CA2973883A1 (en) 2015-01-28 2016-08-04 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
AU2016297862C1 (en) 2015-07-24 2022-12-15 Gliknik Inc. Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin Fc compositions with enhanced complement binding
US11352612B2 (en) 2015-08-17 2022-06-07 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
EP3355904A4 (en) * 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA
US11400140B2 (en) * 2015-10-30 2022-08-02 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
WO2017155569A1 (en) * 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
WO2017171871A1 (en) * 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
WO2017173413A1 (en) * 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
US11034775B2 (en) 2016-06-07 2021-06-15 Gliknik Inc. Cysteine-optimized stradomers
WO2018004517A1 (en) 2016-06-27 2018-01-04 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children and adolescents
EP3500289B1 (en) 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa for use in treating tracheobronchomalacia
BR112019011070A2 (pt) * 2016-11-30 2019-10-01 Purdue Research Foundation regeneração óssea direcionada à fratura através da estimulação do receptor de hormônio da paratireoide
AU2017371179B2 (en) 2016-12-09 2022-07-14 Gliknik Inc. Manufacturing optimization of GL-2045, a multimerizing stradomer
EP3592372A4 (en) * 2017-03-09 2021-01-13 Alexion Pharmaceuticals, Inc. GLYCOPROTEIN MANUFACTURING PROCESS
EP3600383A4 (en) 2017-03-31 2020-10-28 Alexion Pharmaceuticals, Inc. METHODS FOR TREATMENT OF HYPOPHOSPHATASIA (HPP) IN ADULTS AND ADOLESCENTS
WO2019067502A1 (en) 2017-09-27 2019-04-04 Alexion Pharmaceuticals, Inc. METHODS FOR IMPROVING CARDIOVASCULAR FUNCTION AND TREATING CARDIOVASCULAR DISEASE USING RECOMBINANT ECTO-NUCLEOTIDE PYROPHOSPHATASE / PHOSPHODIESTERASE
US11338020B2 (en) 2018-01-09 2022-05-24 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
JP7214962B2 (ja) * 2018-01-17 2023-01-31 東ソー株式会社 アルカリホスファターゼ高発現動物細胞
CA3094173A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Intestinal alkaline phosphatase formulations
WO2019183209A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
JP2021519590A (ja) * 2018-03-30 2021-08-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 糖タンパク質の製造
CN110499285A (zh) * 2018-05-17 2019-11-26 西安组织工程与再生医学研究所 Alpl基因在制备预防和/或治疗低碱性磷酸酶症的产品中的应用
WO2021119218A1 (en) * 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
WO2022051555A2 (en) * 2020-09-03 2022-03-10 Rampart Bioscience, Inc. Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs
KR102571967B1 (ko) * 2021-01-21 2023-08-30 주식회사 마라나노텍코리아 Alp 측정용 바이오 센서
AU2022218782A1 (en) 2021-02-12 2023-08-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
WO2024050464A2 (en) * 2022-08-31 2024-03-07 University Of Utah Research Foundation Gja1-20k compositions and methods for mitigating ischemia-reperfusion injury

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008A (en) * 1850-01-08 Improvement in alloys for points of lightning-rods
WO1995000655A1 (en) 1993-06-24 1995-01-05 Mc Master University Adenovirus vectors for gene therapy
ATE437232T1 (de) 1993-10-25 2009-08-15 Canji Inc Rekombinanter adenoviren-vektor und verfahren zur verwendung
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
ES2284545T3 (es) 1999-11-16 2007-11-16 Genzyme Corporation Vectores y transgenes con elementos reguladores para la administracion de genes del higado.
EP1395293B1 (en) 2001-05-14 2009-07-22 Gbp Ip, Llc Lentiviral vectors encoding clotting factors for gene therapy
CA2433479A1 (en) 2002-07-22 2004-01-22 F. Hoffmann-La Roche Ag Conjugate of a tissue non-specific alkaline phosphatase and dextran, process for its production and use thereof
EP2348114B1 (en) * 2004-04-21 2018-07-25 Alexion Pharmaceuticals, Inc. Bone delivery conjugates and method of using same to target proteins to bone
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
WO2006002203A2 (en) 2004-06-23 2006-01-05 Genzyme Corporation Methods and compositions for the treatment of polycystic diseases
US20090142347A1 (en) * 2004-09-29 2009-06-04 The Burnham Institute For Medical Research Tissue-Nonspecific Alkaline Phosphatase (TNAP): a Therapeutic Target for Arterial Calcification
MX2007006524A (es) 2004-12-01 2007-06-22 Genzyme Corp Metodos para el suministro dirigido de material genetico al higado.

Also Published As

Publication number Publication date
PL2158319T3 (pl) 2012-05-31
AU2008250945A2 (en) 2009-12-24
BRPI0811198B1 (pt) 2021-03-09
HK1141047A1 (en) 2010-10-29
WO2008138131A9 (en) 2009-08-06
ME01828B (me) 2014-12-20
DK2158319T3 (da) 2012-03-19
SI2368999T1 (sl) 2014-07-31
ES2380546T3 (es) 2012-05-16
LU92976I2 (en) 2016-04-11
EP2662448A1 (en) 2013-11-13
HUE031655T2 (hu) 2017-07-28
PL2662448T3 (pl) 2017-07-31
HUS1600005I1 (hu) 2016-02-29
BR122019000505B1 (pt) 2022-01-18
DK2662448T3 (en) 2017-03-20
PL2368999T3 (pl) 2014-08-29
PT2368999E (pt) 2014-05-26
CA2687001C (en) 2019-02-12
LTC2368999I2 (lt) 2017-09-25
RS53302B (en) 2014-08-29
EP2368999A1 (en) 2011-09-28
PT2662448T (pt) 2017-03-29
EP2662448B1 (en) 2016-12-21
IL202057A0 (en) 2011-08-01
BRPI0811198A2 (pt) 2014-10-21
HRP20140416T1 (hr) 2014-06-20
LTPA2016004I1 (lt) 2016-02-25
EP2368999B1 (en) 2014-03-12
WO2008138131A1 (en) 2008-11-20
AU2008250945A1 (en) 2008-11-20
US20100297119A1 (en) 2010-11-25
CA2687001A1 (en) 2008-11-20
HK1191372A1 (zh) 2014-07-25
BRPI0811198A8 (pt) 2018-07-31
JP2010526543A (ja) 2010-08-05
AU2008250945B2 (en) 2013-12-12
CY2016005I2 (el) 2016-08-31
JP5732603B2 (ja) 2015-06-10
BRPI0811198B8 (pt) 2021-05-25
EP2158319A1 (en) 2010-03-03
NL300798I2 (es) 2016-03-16
NO2016002I2 (no) 2016-02-02
HK1162589A1 (en) 2012-08-31
NL300798I1 (es) 2016-03-16
DE202008018131U1 (de) 2011-12-30
PT2158319E (pt) 2012-03-06
NO2016002I1 (es) 2016-02-02
BR122019000505A2 (pt) 2021-12-14
WO2008138131A4 (en) 2008-12-31
ATE536413T1 (de) 2011-12-15
EP2158319B1 (en) 2011-12-07
DK2368999T3 (da) 2014-05-26
PL2158319T4 (pl) 2016-04-29
SI2662448T1 (sl) 2017-05-31
ES2471915T3 (es) 2014-06-27
CY2016005I1 (el) 2016-08-31
EP2158319A4 (en) 2010-07-21

Similar Documents

Publication Publication Date Title
ES2619332T3 (es) Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma
ES2524458T3 (es) DNasa para el tratamiento de la subfertilidad masculina
HRP20090245T1 (en) Pyy agonists and uses thereof
AR031151A1 (es) Articulo absorbente
HUP0300246A2 (en) Delivery system
RS51157B (sr) Baff receptor (bcma), imunoregulatorni agens
ATE264863T1 (de) 28-epirapaloge
CY1113003T1 (el) Ευσταθη παρασκευασματα laquinimod
RS51635B (sr) Antitela koja blokiraju cripto i njihova upotreba
BR0116452A (pt) Composto, composição farmacêutica, uso de um composto
NO20073244L (no) Konjugeringsprodukt
NO2011025I1 (no) Telavancin, eller et farmasøytisk aksseptabelt salt derav, herunder inkludert telavancin hydroklorid
BRPI0417823A (pt) métodos para uso de bifidobactérias probióticas para animais de estimação
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
SG158141A1 (en) Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
CU23260B7 (es) PREPARADO FARMACéUTICO DE MOXIFLOXACINA
DK1791571T3 (da) Radiofluorinerede peptider
TR200401793T4 (tr) Perindopril tuzu ve bunu içeren farmasötik bileşimler.
BR0114903A (pt) 7-azaindóis, sua aplicação como inibidores da fosfodiesterase 4 e processos para a sua preparação
ATE537249T1 (de) Wiedergewinnung von gewebefunktion nach verabreichung von b-zellen an verletztes gewebe
ES2422081T3 (es) Péptido Ser-Ser-Ser-Arg y sus utilizaciones medicinales
UA94231C2 (ru) Олигонуклеотиды или их функциональные гомологи, композиция, которая содержит их, и способ лечения в-клеточной опухоли
MXPA05011783A (es) Peptidos que tienen un efecto inhibidor de enzima convertidora de angiotensina.
DK1200408T3 (da) Vedhæftningsmiddel
RS51534B (en) NEW COMPOUND OF SINUSOID IF CURRENT INHIBITORS AND CALCIUM INHIBITOR AND PHARMACEUTICAL MIXTURE CONTAINED BY IT